Compare DexCom, Inc. (DXCM) vs Zillow Group Inc Class A (ZG) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

Zillow Group (ZG) trades at $31.80, down 0.44% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net income of $23 million in 2025, marking a return to profitability after losses in prior years, though valuation ratios like a P/E of 134.94 suggest high expectations. Recent news highlights multiple securities fraud class action lawsuits filed against the company, alleging anticompetitive practices, which has heightened investor scrutiny.

The outlook is mixed: analyst consensus is bullish with a $57.80 price target, but legal risks and a high P/E ratio pose significant headwinds. Revenue growth to $2.58 billion in 2025 and improving margins offer fundamental support, yet the stock faces pressure from ongoing litigation and volatile cash flows, requiring careful risk assessment for potential investors.